CN107530288B - 口腔崩解片 - Google Patents

口腔崩解片 Download PDF

Info

Publication number
CN107530288B
CN107530288B CN201780000516.8A CN201780000516A CN107530288B CN 107530288 B CN107530288 B CN 107530288B CN 201780000516 A CN201780000516 A CN 201780000516A CN 107530288 B CN107530288 B CN 107530288B
Authority
CN
China
Prior art keywords
tablet
ticagrelor
tablets
amount
blister
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780000516.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107530288A (zh
Inventor
F.A.K.M.阿尔赫斯本
L.H.C.格拉德
J.M.C.哈尔斯坦
A.J.莫伊尔
M.P.汤普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58640851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107530288(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to CN201710899077.0A priority Critical patent/CN107595790B/zh
Priority to CN201710898954.2A priority patent/CN107595789B/zh
Publication of CN107530288A publication Critical patent/CN107530288A/zh
Application granted granted Critical
Publication of CN107530288B publication Critical patent/CN107530288B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/325—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil
    • B65D75/327—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil and forming several compartments

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Composite Materials (AREA)
  • Physiology (AREA)
  • Mechanical Engineering (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780000516.8A 2016-04-21 2017-04-20 口腔崩解片 Active CN107530288B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710899077.0A CN107595790B (zh) 2016-04-21 2017-04-20 口腔崩解片
CN201710898954.2A CN107595789B (zh) 2016-04-21 2017-04-20 口腔崩解片

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325584P 2016-04-21 2016-04-21
US62/325584 2016-04-21
PCT/EP2017/059443 WO2017182589A1 (en) 2016-04-21 2017-04-20 Orally disintegrating tablets

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201710898954.2A Division CN107595789B (zh) 2016-04-21 2017-04-20 口腔崩解片
CN201710899077.0A Division CN107595790B (zh) 2016-04-21 2017-04-20 口腔崩解片

Publications (2)

Publication Number Publication Date
CN107530288A CN107530288A (zh) 2018-01-02
CN107530288B true CN107530288B (zh) 2022-01-25

Family

ID=58640851

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201780000516.8A Active CN107530288B (zh) 2016-04-21 2017-04-20 口腔崩解片
CN201710898954.2A Active CN107595789B (zh) 2016-04-21 2017-04-20 口腔崩解片
CN201710899077.0A Active CN107595790B (zh) 2016-04-21 2017-04-20 口腔崩解片

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201710898954.2A Active CN107595789B (zh) 2016-04-21 2017-04-20 口腔崩解片
CN201710899077.0A Active CN107595790B (zh) 2016-04-21 2017-04-20 口腔崩解片

Country Status (26)

Country Link
US (1) US10729655B2 (https=)
EP (2) EP3445338B1 (https=)
JP (2) JP6960941B2 (https=)
KR (2) KR102392347B1 (https=)
CN (3) CN107530288B (https=)
AU (2) AU2017253367B2 (https=)
BR (1) BR112018071440A2 (https=)
CO (1) CO2018012431A2 (https=)
DK (1) DK3445338T3 (https=)
EA (1) EA201892150A1 (https=)
ES (1) ES3014055T3 (https=)
FI (1) FI3445338T3 (https=)
HR (1) HRP20250204T1 (https=)
HU (1) HUE070095T2 (https=)
IL (1) IL262312B (https=)
LT (1) LT3445338T (https=)
MA (1) MA44720B1 (https=)
PE (1) PE20190372A1 (https=)
PH (1) PH12018502226A1 (https=)
PL (1) PL3445338T3 (https=)
PT (1) PT3445338T (https=)
RS (1) RS66536B1 (https=)
SG (2) SG11201808996SA (https=)
SI (1) SI3445338T1 (https=)
SM (1) SMT202500081T1 (https=)
WO (1) WO2017182589A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111450067A (zh) * 2019-01-18 2020-07-28 北京万全德众医药生物技术有限公司 一种替格瑞洛分散片及其制备方法
CN109700773B (zh) * 2019-03-01 2021-03-16 石药集团中奇制药技术（石家庄）有限公司 一种替格瑞洛制剂组合物及其制备方法
CA3098818A1 (en) 2020-08-19 2022-02-19 Astrazeneca Ab Combination treatment
CN114712317A (zh) * 2021-01-04 2022-07-08 弘和制药有限公司 一种替格瑞洛药物组合物及其制备方法和其应用
KR102659095B1 (ko) * 2021-01-08 2024-04-19 에이비온 주식회사 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법
US20220387328A1 (en) 2021-06-04 2022-12-08 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Dosage form for nicotine replacement therapy
WO2023057879A1 (en) * 2021-10-04 2023-04-13 Neurim Pharmaceuticals (1991) Ltd. Methods and products for treating subjects with autism spectrum disorders
WO2024089196A1 (en) 2022-10-28 2024-05-02 Astrazeneca Ab Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg
CN116370423B (zh) * 2023-02-28 2024-11-12 天津力生制药股份有限公司 一种替格瑞洛口腔崩解片及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN2717851Y (zh) * 2004-05-14 2005-08-17 重庆康刻尔制药有限公司 一种药品包装板
CN101505754A (zh) * 2006-08-21 2009-08-12 阿斯利康(瑞典)有限公司 包括三唑并[4,5-d]嘧啶衍生物的适于口服给药的组合物
CN102058889A (zh) * 2010-11-05 2011-05-18 王定豪 包含抗凝血类药物的分散片及其应用
CN104661649A (zh) * 2012-10-16 2015-05-27 赞蒂瓦有限合伙公司 包含替格瑞洛的固态口服医药制剂
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB516834A (en) * 1937-12-23 1940-01-12 Charles Alexandre Nicolle Improvements in or relating to packaging
DE2246013A1 (de) 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
MXPA03001838A (es) * 2001-05-10 2003-09-10 Yamanouchi Pharmaceuticals Co Tabletas que se desintegran rapidamente en la cavidad bucal y proceso para producir las mismas.
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
FR2968992B1 (fr) 2010-12-16 2013-02-08 Sanofi Aventis Comprime pharmaceutique orodispersible a base de zolpidem
US20130160408A1 (en) * 2011-12-22 2013-06-27 Gregor N. Neff Blister Pack and Method
EP2810659B1 (en) 2012-02-03 2017-08-09 Asahi Kasei Kabushiki Kaisha Orally disintegrating tablet containing bitterness-masking granules
CN103964066B (zh) * 2013-02-06 2017-09-19 李和伟 一种冻干赋型制剂的包装装置
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104650091B (zh) * 2014-01-24 2016-10-05 福州乾正药业有限公司 替格瑞洛的微粉化及其晶型，以及制备方法和药物应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN2717851Y (zh) * 2004-05-14 2005-08-17 重庆康刻尔制药有限公司 一种药品包装板
CN101505754A (zh) * 2006-08-21 2009-08-12 阿斯利康(瑞典)有限公司 包括三唑并[4,5-d]嘧啶衍生物的适于口服给药的组合物
CN102058889A (zh) * 2010-11-05 2011-05-18 王定豪 包含抗凝血类药物的分散片及其应用
CN104661649A (zh) * 2012-10-16 2015-05-27 赞蒂瓦有限合伙公司 包含替格瑞洛的固态口服医药制剂
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
铝箔包装技术拓展的新天地;朱俊;《铝加工》;20111231(第2期);第55-58页 *

Also Published As

Publication number Publication date
MA44720A (fr) 2019-02-27
US20190117577A1 (en) 2019-04-25
JP2022009050A (ja) 2022-01-14
WO2017182589A1 (en) 2017-10-26
IL262312B (en) 2022-08-01
KR102488486B1 (ko) 2023-01-12
SI3445338T1 (sl) 2025-03-31
HK1249732A1 (zh) 2018-11-09
AU2017253367A1 (en) 2018-11-08
EP4417537A2 (en) 2024-08-21
HUE070095T2 (hu) 2025-05-28
PE20190372A1 (es) 2019-03-08
JP2019516674A (ja) 2019-06-20
KR20220054907A (ko) 2022-05-03
AU2017253367B2 (en) 2020-04-16
HK1248562A1 (zh) 2018-10-19
CN107595789A (zh) 2018-01-19
CN107595789B (zh) 2021-01-15
FI3445338T3 (fi) 2025-01-29
MA44720B1 (fr) 2025-02-28
SG10202107682QA (en) 2021-08-30
PH12018502226A1 (en) 2019-07-29
CN107595790A (zh) 2018-01-19
SMT202500081T1 (it) 2025-03-12
SG11201808996SA (en) 2018-11-29
AU2020201930A1 (en) 2020-04-09
EA201892150A1 (ru) 2019-05-31
CN107530288A (zh) 2018-01-02
LT3445338T (lt) 2025-02-25
IL262312A (en) 2018-11-29
JP6960941B2 (ja) 2021-11-05
PL3445338T3 (pl) 2025-03-31
AU2020201930B2 (en) 2020-10-29
ES3014055T3 (en) 2025-04-16
CN107595790B (zh) 2021-01-12
HRP20250204T1 (hr) 2025-04-11
PT3445338T (pt) 2025-03-03
EP4417537A3 (en) 2024-12-04
RS66536B1 (sr) 2025-03-31
JP7254871B2 (ja) 2023-04-10
WO2017182589A9 (en) 2018-04-19
CO2018012431A2 (es) 2018-11-30
EP3445338B1 (en) 2024-11-27
US10729655B2 (en) 2020-08-04
KR20180132147A (ko) 2018-12-11
KR102392347B1 (ko) 2022-05-02
DK3445338T3 (da) 2025-02-10
BR112018071440A2 (pt) 2019-02-05
EP3445338A1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
CN107530288B (zh) 口腔崩解片
EP3862318A1 (en) Porous silica particle composition
CN105007899A (zh) 用于提高生物利用度的口腔崩解片制剂
HRP20040322A2 (en) Flashmelt oral dosage formulation
EP3345626A1 (en) Super-rapid disintegrating tablet, and method for producing same
HK1249733A1 (en) Orally disintegrating tablets
HK1249733B (zh) 口腔崩解片
HK1249732B (zh) 口腔崩解片
HK40112233A (en) Orally disintegrating tablets
HK1248562B (zh) 口腔崩解片
HK40003416A (en) Orally disintegrating tablets
HK40003416B (en) Orally disintegrating tablets
EA042784B1 (ru) Распадающаяся в полости рта таблетка
Guggilla Fast dissolving tablets
Kumar et al. Mouth Dissolving Tablets-Pediatric and Geriatric Patient Compliance Dosage Forms
CN121175036A (zh) 药物组合物
Dewedar et al. FORMULATION AND EVALUATION OF CANDESARTAN CO-PRECIPITATE WITH HYDROPHILIC POLYMERS; PREPARATION OF ORODISPERSIBLE TABLETS
Diliprao Formulation and Evaluation of Orodispersible Tablets of Amlodipine Besilate
Gowtham Preparation And Evaluation Of Immediate Release Folic Acid Tablets
HK1215529B (en) Oral transmucosal drug delivery system
HK1215529A1 (en) Oral transmucosal drug delivery system

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1248562

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant